

# Stefan Aebi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4015957/publications.pdf>

Version: 2024-02-01

117  
papers

5,060  
citations

136740

32  
h-index

91712

69  
g-index

129  
all docs

129  
docs citations

129  
times ranked

7327  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Implementation of DPYD Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	11
2	Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-â€“positive Early Breast Cancer: Results from the SOLE Trial. <i>Clinical Cancer Research</i> , 2021, 27, 504-512.	3.2	5
3	Abstract OT-26-02: Phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor-positive / HER2-negative resected isolated locoregional recurrence of breast cancer - The POLAR Trial. , 2021, , .		0
4	Evaluation of multiple transcriptomic gene risk signatures in male breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 98.	2.3	4
5	Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy. <i>Annals of Oncology</i> , 2021, 32, 1256-1266.	0.6	16
6	P-227: Alternate day dosing of pomalidomide in patients with refractory/relapsed multiple myeloma (RRMM): Results of a multicenter, single arm phase 2 trial (SAKK 39/16 OptiPOM Study). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S165.	0.2	0
7	Locally advanced breast cancer. <i>Breast</i> , 2021, , .	0.9	9
8	Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis. <i>Pharmacological Research</i> , 2020, 152, 104594.	3.1	17
9	345P Optimal dose of eribulin as first line treatment in elderly patients â‰¥ 70 years with advanced breast cancer: A multicenter phase II trial [SAKK 25/14]. <i>Annals of Oncology</i> , 2020, 31, S385.	0.6	0
10	Abstract P5-12-01: SOLE (study of letrozole extension), a phase 3 randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer (BC): Final analysis and sole estrogen substudy (SOLE-EST). , 2020, , .		0
11	Abstract P4-10-03: The genomic landscape of male breast cancers using the oncomine comprehensive assay for actionable mutations. , 2020, , .		0
12	Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy. <i>Swiss Medical Weekly</i> , 2020, 150, w20375.	0.8	26
13	Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data. <i>BMC Cancer</i> , 2019, 19, 902.	1.1	6
14	Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases. <i>BMC Cancer</i> , 2019, 19, 549.	1.1	7
15	Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. <i>British Journal of Cancer</i> , 2019, 120, 959-967.	2.9	5
16	Locoregional Recurrence After Mastectomy. , 2018, , 808-813.e3.		0
17	Population-level effect of molecular testing and targeted therapy in patients with advanced pulmonary adenocarcinoma: a prospective cohort study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 581-588.	1.4	5
18	Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. <i>Annals of Oncology</i> , 2018, 29, 405-417.	0.6	246

#	ARTICLE	IF	CITATIONS
19	Angiosarcoma of the scalp responding to nivolumab: a case report. <i>British Journal of Dermatology</i> , 2018, 179, 530-531.	1.4	11
20	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 127-138.	5.1	91
21	Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1073-1079.	0.8	102
22	Letter comments on EJC published article: Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2-positive breast carcinomatous meningitis. <i>European Journal of Cancer</i> , 2018, 103, 279-280.	1.3	1
23	Nivolumab for recurrent cutaneous squamous cell carcinoma: three cases. <i>European Journal of Dermatology</i> , 2018, 28, 78-81.	0.3	42
24	The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity. <i>Pharmacogenomics Journal</i> , 2017, 17, 319-324.	0.9	3
25	Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 796-804.	2.3	30
26	P3.07-001 Nivolumab for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis including PD-L1 Testing. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1430-S1431.	0.5	1
27	Spotlight on pomalidomide: could less be more?. <i>Leukemia</i> , 2017, 31, 1987-1989.	3.3	5
28	Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99. <i>Annals of Oncology</i> , 2017, 28, 305-312.	0.6	25
29	A Vexing CA 125 Raise in a Patient with Pleural Effusion and Ovarian Cancer. <i>Respiration</i> , 2017, 94, 312-312.	1.2	1
30	Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10). <i>BMC Cancer</i> , 2017, 17, 265.	1.1	13
31	Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial. <i>Annals of Surgical Oncology</i> , 2017, 24, 398-406.	0.7	29
32	Long-term responders to trastuzumab monotherapy in the first-line metastatic setting: characteristics and survival data (SAKK 22/99 Trial). <i>Annals of Oncology</i> , 2017, 28, v99.	0.6	0
33	SOLE (Study of Letrozole Extension): A phase III randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 503-503.	0.8	9
34	Chemotherapy (CT) for isolated locoregional recurrence (ILRR) of breast cancer in ER-positive (ER+) and ER-negative (ER-) cohorts: Final analysis of the CALOR trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 513-513.	0.8	1
35	Response to Pembrolizumab in a Patient with Relapsing Thymoma. <i>Journal of Thoracic Oncology</i> , 2016, 11, e147-e149.	0.5	33
36	A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1846-1855.	0.5	80

#	ARTICLE	IF	CITATIONS
37	Intravascular large B-cell lymphoma. Memo - Magazine of European Medical Oncology, 2016, 9, 59-62.	0.3	0
38	The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MO AIC, a multicenter cluster-randomized phase III study (SAKK 95/06). Annals of Oncology, 2016, 27, 324-332.	0.6	101
39	Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity. International Journal of Cancer, 2015, 136, 730-739.	2.3	95
40	1971 A correlative study of Ki67 and two multigene RNA expression signatures in operable ER-positive postmenopausal breast cancer (SAKK 26/10). European Journal of Cancer, 2015, 51, S324.	1.3	0
41	Successful AZD9291 Therapy Based on Circulating T790M. Journal of Thoracic Oncology, 2015, 10, e122-e124.	0.5	2
42	1943 Adjuvant treatment recommendations for ER+ early breast cancer patients by Swiss tumor boards (SAKK 26/10). European Journal of Cancer, 2015, 51, S313.	1.3	1
43	Rapid Response to Trastuzumab Emtansine in a Patient with HER2-Driven Lung Cancer. Journal of Thoracic Oncology, 2015, 10, e16-e17.	0.5	25
44	Mutation Profiling of Lung Cancers with Long-Term Response to Gefitinib Therapy. Oncology Research and Treatment, 2015, 38, 560-569.	0.8	5
45	Complement Activation and Rituximab Distribution in CNS NHL Letter. Clinical Cancer Research, 2015, 21, 490-490.	3.2	3
46	Dihydropyrimidinase and Î²-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity. Pharmacogenomics, 2015, 16, 1367-1377.	0.6	12
47	Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2). British Journal of Cancer, 2015, 113, 716-721.	2.9	23
48	Abstract S6-05: Characterization of male breast cancer: First results of the EORTC10085/TBCRC/BIG/NABCG International Male BC Program. , 2015, , .		20
49	Abstract B135: Successful AZD9291 therapy based on NEOLiquid detection of circulating T790M in a liquid biopsy sample. , 2015, , .		0
50	Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences. Breast Cancer Research and Treatment, 2014, 144, 321-329.	1.1	7
51	First international consensus guidelines for breast cancer in young women (BCY1). Breast, 2014, 23, 209-220.	0.9	135
52	Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. Lancet Oncology, The, 2014, 15, 156-163.	5.1	171
53	Maastricht Delphi Consensus on Event Definitions for Classification of Recurrence in Breast Cancer Research. Journal of the National Cancer Institute, 2014, 106, .	3.0	73
54	Reply to "Staging for distant metastases in operable breast cancer: a suggested expansion of the ESMO guideline recommendation for staging imaging of node-negative, hormonal receptor-negative disease" by U. Gueth et al. Annals of Oncology, 2013, 24, 557.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Optimal Sequence of Tamoxifen and Aromatase Inhibitors to Prevent Bone Loss. Journal of Clinical Oncology, 2013, 31, 3440-3441.	0.8	2
56	A Patient with Lung Adenocarcinoma and RET Fusion Treated with Vandetanib. Journal of Thoracic Oncology, 2013, 8, e43-e44.	0.5	101
57	Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). Annals of Oncology, 2012, 23, 1474-1481.	0.6	35
58	A Patient With BRAF V600E Lung Adenocarcinoma Responding to Vemurafenib. Journal of Thoracic Oncology, 2012, 7, e23-e24.	0.5	131
59	Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting. Supportive Care in Cancer, 2012, 20, 141-147.	1.0	56
60	Abstract P6-07-06: Patterns of locoregional failure in the CALOR (Chemotherapy as Adjuvant for) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50		
61	Abstract S3-2: Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: The CALOR trial (Chemotherapy as Adjuvant for Locally Recurrent breast cancer; IBCSG 27-02,) Tj ETQq1 1 0.784314rgBT /Over		
62	Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2011, 22, vi12-vi24.	0.6	197
63	Trastuzumab Treatment beyond Progression in Advanced Breast Cancer: Patterns of Care in Six Swiss Breast Cancer Centers. Oncology, 2011, 81, 160-166.	0.9	8
64	Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX. Annals of Oncology, 2011, 22, 1981-1987.	0.6	47
65	PRO_10 " A New Tissue-Based Prognostic Multigene Marker in Patients with Early Estrogen Receptor-Positive Breast Cancer. Pathobiology, 2011, 78, 140-148.	1.9	5
66	Bone mineral density (BMD) in participants (pts) of trial BIG 1-98 comparing adjuvant letrozole (L) versus tamoxifen (T) or their sequence.. Journal of Clinical Oncology, 2011, 29, 516-516.	0.8	2
67	Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue. BMC Cancer, 2010, 10, 37.	1.1	9
68	Routine adjuvant use of bisphosphonates in breast cancer Arguments in favour and against. Critical Reviews in Oncology/Hematology, 2010, 74, S11-S15.	2.0	2
69	Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2010, 21, v9-v14.	0.6	1,220
70	MET Inhibition Results in DNA Breaks and Synergistically Sensitizes Tumor Cells to DNA-Damaging Agents Potentially by Breaching a Damage-Induced Checkpoint Arrest. Genes and Cancer, 2010, 1, 1053-1062.	0.6	42
71	Trastuzumab (T) treatment beyond progression in metastatic breast cancer (MBC): Patterns of care in Swiss clinical practice.. Journal of Clinical Oncology, 2010, 28, 1146-1146.	0.8	0
72	Abstract P2-16-07: hMMP9 as Predictive Factor for Response and Progression Free Survival in Breast Cancer Patients Treated with Bevacizumab and Pegylated Liposomal Doxorubicin (PLD). , 2010, , .		0

#	ARTICLE	IF	CITATIONS
73	Infiltrating Lobular Carcinoma of the Breast: Systemic Treatment. <i>Breast Disease</i> , 2009, 30, 45-52.	0.4	12
74	The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. <i>Annals of Oncology</i> , 2009, 20, 1344-1351.	0.6	15
75	Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. <i>Pharmacogenomics</i> , 2009, 10, 931-944.	0.6	112
76	The Voice of a Special Patient. <i>Cancer Treatment and Research</i> , 2009, 151, 461-466.	0.2	0
77	Modelling Bone Mineral Density in Swiss Breast Cancer Patients Treated with Letrozole, Tamoxifen and Sequences of Letrozole and Tamoxifen in the BIG 1-98 Study (SAKK 21/07).. , 2009, , .		0
78	Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group. <i>Supportive Care in Cancer</i> , 2008, 16, 67-74.	1.0	11
79	Expression profiling with RNA from formalin-fixed, paraffin-embedded material. <i>BMC Medical Genomics</i> , 2008, 1, 9.	0.7	52
80	Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a Prospective Randomized Trial Evaluating Chemotherapy after Local Therapy for Isolated Locoregional Recurrences of Breast Cancer. <i>Annals of Surgical Oncology</i> , 2008, 15, 3227-3231.	0.7	26
81	A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Locoregional Relapse of Breast Cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37. <i>Clinical Breast Cancer</i> , 2008, 8, 287-292.	1.1	23
82	Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2008, 27, 54.	3.5	28
83	Epithelial ovarian carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2008, 19, ii14-ii16.	0.6	50
84	Adjuvant Chemotherapy Followed By Goserelin Compared With Either Modality Alone: The Impact on Amenorrhea, Hot Flashes, and Quality of Life in Premenopausal Patientsâ€™The International Breast Cancer Study Group Trial VIII. <i>Journal of Clinical Oncology</i> , 2007, 25, 263-270.	0.8	61
85	Controversies of adjuvant endocrine treatment for breast cancer and recommendations of the 2007 St Gallen conference. <i>Lancet Oncology</i> , The, 2007, 8, 940-949.	5.1	40
86	CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. <i>Annals of Oncology</i> , 2007, 18, 701-708.	0.6	95
87	Treatment of Premenopausal Women with Early Breast Cancer. <i>Drugs</i> , 2007, 67, 1393-1401.	4.9	11
88	A nurse is a nurse? A systematic review of the effectiveness of specialised nursing in breast cancer. <i>European Journal of Cancer</i> , 2006, 42, 3117-3126.	1.3	27
89	Chemotherapy - overview and future perspectives. <i>Breast</i> , 2006, 15, S11-S14.	0.9	3
90	Efficacy and Tolerability of Capecitabine with Weekly Paclitaxel for Patients with Metastatic Breast Cancer: A Phase II Report of the SAKK. <i>Oncology</i> , 2006, 71, 54-60.	0.9	9

#	ARTICLE	IF	CITATIONS
91	Tamoxifen After Adjuvant Chemotherapy for Premenopausal Women With Lymph Node-Positive Breast Cancer: International Breast Cancer Study Group Trial 13-93. <i>Journal of Clinical Oncology</i> , 2006, 24, 1332-1341.	0.8	215
92	Multicycle Dose-Intensive Chemotherapy for Women With High-Risk Primary Breast Cancer: Results of International Breast Cancer Study Group Trial 15-95. <i>Journal of Clinical Oncology</i> , 2006, 24, 370-378.	0.8	67
93	Special issues related to the adjuvant therapy in very young women. <i>Breast</i> , 2005, 14, 594-599.	0.9	13
94	Capecitabine with Weekly Paclitaxel for Advanced Breast Cancer: A Phase I Dose-Finding Trial. <i>Oncology</i> , 2004, 67, 117-122.	0.9	17
95	Endometrial cancer: a frequent orphan disease. <i>Annals of Oncology</i> , 2004, 15, 1149-1150.	0.6	1
96	Anastrozole (Arimidex™) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95 - a sub-study of the TARGET (Tamoxifen or Arimidex™ Randomized Group Efficacy and Tolerability) trial. <i>Breast Cancer Research and Treatment</i> , 2004, 85, 247-254.	1.1	69
97	Prognosis of dermal lymphatic invasion with or without clinical signs of inflammatory breast cancer. <i>International Journal of Cancer</i> , 2004, 109, 144-148.	2.3	31
98	Adjuvant endocrine therapy for the very young patients. <i>Breast</i> , 2003, 12, 509-515.	0.9	3
99	Activity of raltitrexed and gemcitabine in advanced pancreatic cancer. <i>Annals of Oncology</i> , 2003, 14, 574-579.	0.6	23
100	Assessment of Differences in Patient Populations Selected for or Excluded From Participation in Clinical Phase III Acute Myelogenous Leukemia Trials. <i>Journal of Clinical Oncology</i> , 2003, 21, 3933-3939.	0.8	108
101	Medical treatment of nasal squamous papilloma with imiquimod cream. <i>Journal of Laryngology and Otology</i> , 2003, 117, 720-722.	0.4	7
102	Long-term follow-up of concurrent radiotherapy and chemotherapy for locally advanced cervical cancer: 12-Year survival after radiochemotherapy. <i>International Journal of Oncology</i> , 2002, 20, 1313.	1.4	1
103	Intensive chemotherapy with whole blood stem-cell support and concurrent chest radiotherapy in small cell lung cancer: a phase I/II trial. <i>Lung Cancer</i> , 2002, 36, 321-326.	0.9	3
104	A high-resolution allelotype of B-cell chronic lymphocytic leukemia (B-CLL). <i>Blood</i> , 2002, 100, 1787-1794.	0.6	32
105	Combination chemotherapy with high-dose methotrexate and cytarabine with or without brain irradiation for primary central nervous system lymphomas. <i>Journal of Neuro-Oncology</i> , 2002, 59, 227-230.	1.4	20
106	Activity of Gemcitabine and Continuous Infusion Fluorouracil in Advanced Pancreatic Cancer. <i>Oncology</i> , 2001, 60, 43-48.	0.9	32
107	Epidermal growth factor enhances cisplatin-induced apoptosis by a caspase 3 independent pathway. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 47, 397-403.	1.1	16
108	Bcl-xl antisense oligonucleotides induce apoptosis and increase sensitivity of pancreatic cancer cells to gemcitabine. <i>International Journal of Cancer</i> , 2001, 94, 268-274.	2.3	60

#	ARTICLE	IF	CITATIONS
109	Determination of 5-fluorouracil and 5-fluoro-2â€²-deoxyuridine-5â€²-monophosphate in pancreatic cancer cell line and other biological materials using capillary electrophoresis. Journal of Chromatography A, 2001, 916, 215-224.	1.8	36
110	Differential expression of p73 splice variants and protein in benign and malignant ovarian tumours. International Journal of Cancer, 2000, 88, 66-70.	2.3	41
111	Increase in tumor GADD153 mRNA level following treatment correlates with response to paclitaxel. Cancer Chemotherapy and Pharmacology, 2000, 45, 381-388.	1.1	12
112	False negatives in oestrogen-receptor assay. Lancet, The, 2000, 356, 944-945.	6.3	2
113	Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?. Lancet, The, 2000, 355, 1869-1874.	6.3	261
114	Divergent Expression of Cclin-Dependent Kinase Inhibitors (CKI) And p14ARF/p16Î² in Non-Hodgkin's Lymphomas and Chronic Lymphocytic Leukemia. Leukemia and Lymphoma, 2000, 37, 639-648.	0.6	4
115	Increased sensitivity to gemcitabine following Bcl-xL antisense treatment in pancreatic cancer cells. Gastroenterology, 2000, 118, A521.	0.6	0
116	Differential expression of p73 splice variants and protein in benign and malignant ovarian tumours. , 2000, 88, 66.		1
117	A randomized crossover trial assessing patient preference for two different types of portable infusion-pump devices. Annals of Oncology, 1999, 10, 727-729.	0.6	27